Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 - 80 years old;
- Patients with active myeloma requiring systemic treatment;
- Newly diagnosed patients. Relapsed myeloma patients that have not previously had a transplant;
- Meeting criteria for high-risk disease;
- Measurable serum and/or urine M-protein from prior to induction therapy documented and available. A positive serum free lite assay is acceptable;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 (see Appendix C).
- Meet all institutional requirements for autologous stem cell transplantation;
- The patient must be able to comprehend and have signed the informed consent;
- Patients must have had > than PR after last therapy.
Exclusion Criteria:
Diagnosis of any of the following cancers:
- POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein [M-protein] and skin changes);
- Non-secretory myeloma (no measurable protein on Serum Free Lite Assay);
- Plasma cell leukemia;
- Diagnosis of amyloidosis;
- Failed to achieve at least a partial response (PR) to latest therapy;
- Previous hematopoietic stem cell transplantation;Patients can have had prior relapsed disease as long as they have never been previously transplanted;
- Known history of HIV infection;
- Use of corticosteroids (glucocorticoids) within 21 days of bone marrow collection;
- Use of any myeloma-specific therapy within 21 days of bone marrow collection;
- Infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of registration;
- Participation in any clinical trial within 28 days of registration on this trial, which involved an investigational drug or device;
- History of malignancy other than multiple myeloma within five years of registration, except adequately treated basal or squamous cell skin cancer;
- Active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring active systemic treatment. Hypothyroidism without evidence of Grave's disease or Hashimoto's thyroiditis is permitted.
- Human T-lymphotropic virus (HTLV) 1 or 2 positive;
- Known hypersensitivity to Prevnar or any of its components;
- Contraindication to phosphodiesterase-5 inhibitors (e.g. currently on nitrates).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: aMIL Arm
Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
|
On day 0, patients will receive auto transplant followed by Tadalafil and aMIL.
At day 60, patients will receive Lenalidomide.
On day 0, patients will receive auto transplant followed by Tadalafil.
At day 60, patients will receive Lenalidomide.
|
|
Active Comparator: No aMIL
Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
|
On day 0, patients will receive auto transplant followed by Tadalafil.
At day 60, patients will receive Lenalidomide.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of MILs as Assessed by the Ability to Harvest, Expand, and Infuse the MILs Product
Time Frame: 120 days
|
Feasibility is defined as the ability to harvest, expand, and infuse the MILs product within 120 days.
After treating 60 patients with MILs, we will declare MILs not feasible if we can only harvest, expand, and deliver MILs to 40 or fewer patients.
|
120 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Toxicity as Determined by Total Number of Grade 3 or Higher Adverse Events
Time Frame: 60 days from aMILs harvest until day 60 after transplant
|
Total number of adverse events grade 3 or higher that occur from MILs harvest through 60 days after transplant.
|
60 days from aMILs harvest until day 60 after transplant
|
|
Overall Survival (OS)
Time Frame: 3 years
|
OS assessed by number of participants alive at the end of follow up period.
|
3 years
|
|
Progression-free Survival (PFS)
Time Frame: 5 years
|
Median PFS time equals the time of randomization (in months) until disease progression, death from any cause, or protocol deviation due to lenalidomide dosing (above 10mg), whichever occurs first.
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Philip Imus, M.D., Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
Other Study ID Numbers
- J1343
- NA_00084466 (Other Identifier: JHMIRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.